Once-daily single tablet regimen of tenofovir/emtricitabine/efavirenz - Potent, safe and convenient approach to combined antiretroviral therapy

HIV and AIDS Review

Volumn 10, Issue 2, 2011, Pages 38-39

  Dabrowska, Magdalena M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Adherence; cART; Efficacy; Once daily; Side effects; Single tablet regimen

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ASTEMIZOLE; BEPRIDIL; CISAPRIDE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; PIMOZIDE; TENOFOVIR DISOPROXIL; TERFENADINE; TRIAZOLAM; VIRUS RNA; VORICONAZOLE;

ABNORMAL DREAMING; ANTIVIRAL ACTIVITY; ANXIETY; ATTENTION DISTURBANCE; BEDTIME DOSAGE; BLOOD LEVEL; BONE DENSITY; COMBINATION CHEMOTHERAPY; CREATININE CLEARANCE; DEPRESSION; DIARRHEA; DNA SYNTHESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; GROWTH INHIBITION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; INSOMNIA; NAUSEA AND VOMITING; NONHUMAN; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; VIROTHERAPY; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 80054003632     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hivar.2011.03.004     Document Type: Review

References (11)

1. Available at: http://www.europeanaidsclinicalsociety.org/guidelines.asp.
2. J.M.Molina, Efficacy and safety of once-daily regimens in the treatment of HIV infection, Drugs 68 (2008) 567-578.
3. FDA, Approves the First Once-a-Day Three-Drug Combination Tablet for Treatment of HIV-1, July 2006, Available from: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2006/ucm108689.htm.
4. J.Y. Feng, J.K. Ly, F. Myrick, D. Goodman, K.L. White, E.S. Svarovskaia, et al., The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study, Retrovirology 6 (2009) 44.
5. Atripla - Summary of Product Characteristics, available on the website of the European Medicines Agency (EMA) (2009) http://www.ema.europa.eu/.
6. N.A. Margot, J. Enejosa, A.K. Cheng, M.D. Miller, D.J. McColl, Study 934 Team, Development of HIV-1 drug resistance through 144 weeks in antiretroviralnaïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934, J. Acquir. Immune Defic. Syndr. 52 (2009) 209-221.
7. D.D. Goodman, Y. Zhou, N.A. Margot, D.J. McColl, L. Zhong, K. Borroto-Esoda, et al., Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy, AIDS 25 (2011) 325-333.
8. E. DeJesus, B. Young, J.O. Morales-Ramirez, L. Sloan, D.J. Ward, J.F. Flaherty, et al., AI266073 Study Group. Simplification of antiretroviral therapy to a singletablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients, J. Acquir. Immune Defic. Syndr. 51 (2009) 163-174.
9. T. Welz, K. Childs, F. Ibrahim,M. Poulton, C.B. Taylor, C.F. Moniz, et al., Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase, AIDS 24 (2010) 1923-1928.
10. S.L. Hodder, K. Mounzer, E. DeJesus, R. Ebrahimi, K. Grimm, S. Esker, et al., AI266073 Study Group. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF, AIDS Patient Care STDS 24 (2010) 87-96.
11. D.R. Bangsberg, K. Ragland, A. Monk, S.G. Deeks, A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people, AIDS 24 (2010) 2835-2840.